PXVX-0317 is a subunit vaccine commercialized by Bavarian Nordic, with a leading Pre-Registration program in Chikungunya Fever. According to Globaldata, it is involved in 9 clinical trials, of which 7 were completed, 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of PXVX-0317’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for PXVX-0317 is expected to reach an annual total of $497 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
PXVX-0317 Overview
CHIKV-VLP is under development for the prevention of chikungunya viral infection. The therapeutic candidate is administered through intramuscular route. The vaccine candidate is a virus like particle vaccine that consists of CHIKV VLP composed of E1, E2 and capsid proteins.
Bavarian Nordic Overview
Bavarian Nordic is a biotechnology company specializing in the research, development, and manufacturing of vaccines. The company’s primary activities include vaccine development, commercial-scale manufacturing, and commercial operations. Bavarian Nordic’s product portfolio includes vaccines for diseases such as tick-borne encephalitis, smallpox, monkeypox, rabies, cholera, and typhoid. The major brands offered by the company include Encepur, Jynneos, Imvamune, Imvanex, Rabipur, RabAvert, Vaxchora, and Vivotif. The company operates its commercial-scale manufacturing facility in Kvistgaard, Denmark. It operates commercial, research, and development centers in Canada, Switzerland, Germany, Italy, Spain, and Sweden. Bavarian Nordic is headquartered in Hellerup, Denmark.
The company reported revenues of (Danish Krone) DKK7,062.3 million for the fiscal year ended December 2023 (FY2023), compared to a revenue of DKK3,150.8 million in FY2022. The operating profit of the company was DKK1,502.5 million in FY2023, compared to an operating loss of DKK70.8 million in FY2022. The net profit of the company was DKK1,475.2 million in FY2023, compared to a net loss of DKK347.4 million in FY2022.
The company reported revenues of DKK1,427.5 million for the second quarter ended June 2024, an increase of 71.7% over the previous quarter.
For a complete picture of PXVX-0317’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
